Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr108.05M

Enterprise Valuekr86.42M

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Zero Debt Balance SheetHaving zero reported debt materially lowers financial risk and interest burden, giving management flexibility to prioritize R&D and clinical programs without immediate fixed financing costs. This structural conservatism supports multi‑quarter runway options and strategic choices in capital markets.

Multi-year Revenue GrowthSustained top-line expansion over several years signals growing commercial traction and demand for the company’s MSC-based offerings. Durable revenue growth supports scale benefits, validates market need, and underpins potential for incremental R&D investment and future commercialization progress.

Improving Free Cash Flow TrendA positive shift in free cash flow growth indicates operational improvements or better working capital management. Even though FCF remains negative, the improvement reduces urgency for near‑term external funding and suggests management is making progress toward improving cash efficiency.

Bears Say

Large, Persistent Cash BurnVery large negative operating and free cash flows relative to scale create a structural funding dependency. Sustained cash burn limits runway, forces recurring capital raises, and constrains consistent investment in clinical development without dilutive financing or strategic partnerships.

Negative Gross Profit And MarginsPersistently negative gross margins indicate the core business model has not reached scalable, profitable unit economics. This structural margin gap implies ongoing reliance on external funding and a long timeline before operations can sustainably generate profits without meaningful cost structure or pricing shifts.

Declining Equity And Dilution RiskA material drop in shareholders' equity over multiple years reflects cumulative losses and/or dilution from financing. This reduces the balance sheet cushion, elevates the probability of future equity raises, and increases long‑term dilution risk for existing shareholders if cash burn persists.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr108.05M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.092.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.